Shares of Axsome Therapeutics Inc (NASDAQ:AXSM) have received a consensus rating of “Buy” from the six brokerages that are currently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating and five have given a buy rating to the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $16.90.
Several equities research analysts recently weighed in on AXSM shares. Zacks Investment Research downgraded shares of Axsome Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, October 17th. Cantor Fitzgerald set a $13.00 price target on shares of Axsome Therapeutics and gave the company a “buy” rating in a research report on Friday, December 1st. Finally, ValuEngine raised shares of Axsome Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Friday, February 2nd.
A number of large investors have recently bought and sold shares of AXSM. Goldman Sachs Group Inc. grew its position in Axsome Therapeutics by 118.7% in the 2nd quarter. Goldman Sachs Group Inc. now owns 67,618 shares of the company’s stock worth $372,000 after purchasing an additional 36,698 shares during the period. Susquehanna International Group LLP bought a new stake in Axsome Therapeutics in the 2nd quarter worth approximately $188,000. Finally, JPMorgan Chase & Co. grew its position in Axsome Therapeutics by 1.6% in the 3rd quarter. JPMorgan Chase & Co. now owns 1,459,117 shares of the company’s stock worth $8,026,000 after purchasing an additional 23,229 shares during the period. 23.62% of the stock is owned by institutional investors and hedge funds.
Axsome Therapeutics (NASDAQ:AXSM) last announced its quarterly earnings results on Wednesday, November 8th. The company reported ($0.27) earnings per share for the quarter. equities analysts predict that Axsome Therapeutics will post -1.31 earnings per share for the current fiscal year.
Axsome Therapeutics Company Profile
Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapies for the management of central nervous system (CNS) disorders, including pain. It operates in the business of developing novel therapies for the management of CNS disorders segment. Its product candidate, AXS-02 (disodium zoledronate tetrahydrate), is an oral, targeted, non opioid therapeutic for chronic pain.
Receive News & Ratings for Axsome Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.